Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysis

Published:2021-10 Issue: Volume:40 Page:101130
ISSN:2589-5370
Container-title:EClinicalMedicine
language:en
Short-container-title:EClinicalMedicine

Author:

Moreau Bachelard Camille,Coquan Elodie,du Rusquec Pauline^ORCID,Paoletti Xavier,Le Tourneau Christophe^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. Cancer statistics, 2021;Siegel;CA Cancer J Clin,2021

2. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor;Loehrer Sr;J Clin Oncol,1998

3. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma;Larkin;New Engl J Med,2019

4. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis;Antonia;Lancet Oncol,2019

5. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer;Gainor;Cancer Discov,2016

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting of human cancer stem cells predicts efficacy and toxicity of FDA-approved oncology drugs;Cancer Letters;2024-09

2. Utilising systematic reviews to assess potential overtreatment and claim for better evidence-based research: an analysis of anticancer drugs versus supportive care in advanced esophageal cancer;Systematic Reviews;2024-07-18

3. Fight for Cancer Diseases using Natural Compounds and Their Semisynthetic Derivatives;Bioactivities;2024-07-12

4. Composite Hydrogel with Oleic Acid-Grafted Mesoporous Silica Nanoparticles for Enhanced Topical Delivery of Doxorubicin;Gels;2024-05-22

5. Potential drug targets for tumors identified through Mendelian randomization analysis;Scientific Reports;2024-05-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3